


Danirixin

Cat. No.:	HY-19768	
CAS No.:	954126-98-8	
Molecular Formula:	C ₁₉ H ₂₁ ClFN ₃ O ₄ S	
Molecular Weight:	441.9	
Target:	CXCR	
Pathway:	GPCR/G Protein; Immunology/Inflammation	
Storage:	Powder	-20°C 3 years 4°C 2 years
	In solvent	-80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 8 mg/mL (18.10 mM; Need ultrasonic and warming)

Solvent	Mass	Concentration		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.2630 mL	11.3148 mL	22.6296 mL
	5 mM	0.4526 mL	2.2630 mL	4.5259 mL
	10 mM	0.2263 mL	1.1315 mL	2.2630 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description	Danirixin is a selective, and reversible CXCR2 antagonist, with IC ₅₀ of 12.5 nM for CXCL8.
IC₅₀ & Target	CXCL8-CXCR2 12.5 nM (IC ₅₀)
In Vitro	Danirixin is a small molecule, CXCR2 antagonist being evaluated as a potential anti-inflammatory medicine ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Cell Death Dis. 2019 Mar 20;10(4):273.
- Front Immunol. 2021 May 7;12:667177.

-
- Cancer Cell Int. 2021 Jul 3;21(1):337.
 - Int Immunopharmacol. 2021 Mar 5;95:107153.
 - Research Square Preprint. 2021 Mar.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Miller BE, et al. The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)--a selective CXCR2 antagonist?--in healthy adult subjects. BMC Pharmacol Toxicol. 2015 Jun 20;16:18.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA